Cellectar Biosciences Inc
9.61 %
-91.66 %
Yet to be announced
Company Overview
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core technology is its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform, which is designed to specifically target cancer cells and deliver payloads for improved efficacy.
The company's lead product candidate is iopofosine I-131, a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. This compound is in clinical trials for various hematologic and solid tumor malignancies.
Revenue Sources
PassCellectar Biosciences is a pre-revenue biotechnology company currently in the research and development phase. The company has reported zero revenue for the past four quarters while focusing on developing its cancer treatments. Since the company is pre-revenue and still in the R&D phase, this criteria is not applicable at this time.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Analysis of the financial statements for the past four quarters shows that Cellectar has reported zero interest income and zero interest expense. As the company is still in its pre-revenue research and development phase, this criteria is not applicable at this time.
Operational Ethics
PassBased on available information from SEC filings and company disclosures, there is no evidence of any significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party. The company's operations and clinical trials are primarily conducted in the United States.
Login to join the discussion